A cost-effective antibiotic, levofloxacin, has been identified as a potent tool in reducing the risk of contracting drug-resistant tuberculosis (MDR-TB). Tuberculosis, the second deadliest infectious disease globally, poses a significant threat, especially in developing countries where access to treatment is limited. South African research, presented at the Union World Conference on Lung Health, reveals a groundbreaking 56% risk reduction in children exposed to MDR-TB. Collaborating with a study in Vietnam, a Bayesian analysis indicates an overall 60% risk reduction for all ages. This pivotal research, funded in part by Unitaid, holds promise for millions, particularly children.